Literature DB >> 25084202

Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments.

Kenneth K W To1, Miao Hu, Brian Tomlinson.   

Abstract

AIM: This study investigated whether cholesterol levels influence the expression and function of drug transporters and whether statin treatments could alter this by reducing plasma low-density lipoprotein cholesterol levels. PATIENTS &
METHODS: The mRNA expression and function of OATP1B1, ABCB1 and ABCG2 were assessed in peripheral blood mononuclear cells (PBMCs) of healthy subjects and from patients with familial hypercholesterolemia (FH) before and after statin treatment by real-time PCR and flow cytometric assay, respectively. The effects of statin exposure and cholesterol depletion in PBMCs and in cell lines were assessed.
RESULTS: ABCG2 expression and activity in PBMCs in patients with FH were 2-fold and 26-fold higher, respectively, than those of the healthy subjects (p < 0.001 for both). Statin treatment decreased ABCG2 expression and function in patients with FH. Depletion of cholesterol ex vivo reduced ABCG2 expression in PBMCs and reduced ABCG2 activity in liver and colon cells.
CONCLUSION: This study suggested that statins may downregulate ABCG2 expression and function through reducing low-density lipoprotein cholesterol levels.

Entities:  

Keywords:  ABCB1; ABCG2; OATP1B1; cholesterol; drug transporters; familial hypercholesterolemia; statins

Mesh:

Substances:

Year:  2014        PMID: 25084202     DOI: 10.2217/pgs.14.58

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  7 in total

Review 1.  Next-generation gene discovery for variants of large impact on lipid traits.

Authors:  Elisabeth Rosenthal; Elizabeth Blue; Gail P Jarvik
Journal:  Curr Opin Lipidol       Date:  2015-04       Impact factor: 4.776

2.  Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women.

Authors:  Shabnam Nazir; Zafar Iqbal; Fazli Nasir
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

3.  NLRP3 Inflammasome Priming and Activation Are Regulated by a Phosphatidylinositol-Dependent Mechanism.

Authors:  Claire Hamilton; Antoni Olona; Stuart Leishman; Kelly MacDonald-Ramsahai; Shamshad Cockcroft; Gerald Larrouy-Maumus; Paras K Anand
Journal:  Immunohorizons       Date:  2022-08-29

Review 4.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

5.  Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians.

Authors:  J Vendelbo; R H Olesen; J K Lauridsen; J Rungby; J E Kleinman; T M Hyde; A Larsen
Journal:  Pharmacogenomics J       Date:  2016-11-29       Impact factor: 3.550

6.  Statin Responses in Chinese Patients.

Authors:  Brian Tomlinson; Paul Chan; Zhong-Min Liu
Journal:  J Atheroscler Thromb       Date:  2017-07-21       Impact factor: 4.928

7.  Polymorphisms of the genes ABCG2, SLC22A12 and XDH and their relation with hyperuricemia and hypercholesterolemia in Mexican young adults.

Authors:  Juan Manuel Vargas-Morales; Martha Guevara-Cruz; Celia Aradillas-García; Lilia G Noriega; Armando Tovar; Jorge Alejandro Alegría-Torres
Journal:  F1000Res       Date:  2021-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.